One shot before transplant could save kidneys

NCT ID NCT06919003

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single injection of Berinert, a protein that reduces inflammation, into a donor kidney just before transplant can improve kidney function in the first year. Researchers will compare this to a placebo in 180 high-risk patients receiving deceased-donor kidneys. The goal is to see if the treatment helps the kidney work better and reduces long-term damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Berinert (C1 esterase inhibitor)
What this could lead to: If it works, this could improve kidney function and reduce complications after transplant, potentially helping more donated kidneys last longer.
What could go wrong: This is a Phase 2 trial, so it's still early. The treatment may not improve outcomes, and there could be side effects from the injection or the drug itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT

Contacts and locations

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Kansas University Medical Center
RECRUITING

Kansas City, Kansas, 66160, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467-2401, United States
Northwestern Memorial Hospital
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.